A review of financial information, stocks, the economy, and all things finance to guide investment decisions.

Bristol-Myers Squibb ($BMY), a pharmaceutical giant, is trading at $49.73, far below its intrinsic value of $146.45, as calculated using the Buffett and ...

Sotyktu’s safety profile through 16 weeks of treatment remained consistent with previous reports throughout its clinical ...

Chris Colfer is still in touch with some of the "living legends" he worked with on Glee. The 35-year-old actor shot to fame ...

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...

Bristol Myers Squibb has appointed Wendy Bartie as EVP, corporate affairs. Bartie started in the role this month, BMS said on ...

Bristol-Myers Squibb dropped some good news for patients and investors with its latest Phase 3 POETYK PsA-1 trial results for ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

Fortune has partnered with Indiggo to measure Return On Leadership, called the ROL100. Read which dividend stocks we ...